Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Docetaxel proves more effective than paclitaxel in women with node-positive breast cancer
February 9th, 2006
Docetaxel proves more effective than paclitaxel in women with operable node-positive breast cancer. "Breast cancer is the most common cancer affecting women. A comparison of docetaxel and 5-fluorouracil in women with operable node-positive breast cancer, also taking doxorubicin and cyclophosphamide, was started in 1997," an investigator in New Zealand reports. S.A. Doggrell of the Auckland University of Technology stated, "The primary end point was disease-free survival; the time from randomization to clinical relapse, a second cancer, or death. In a median follow up of 55 months, fewer events had occurred in the docetaxel (172/745) than the...
Source: Women's Health Weekly (2006-02-09)
|
